1. Home
  2. CYCC vs TSBX Comparison

CYCC vs TSBX Comparison

Compare CYCC & TSBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CYCC
  • TSBX
  • Stock Information
  • Founded
  • CYCC 1992
  • TSBX 2015
  • Country
  • CYCC Malaysia
  • TSBX United States
  • Employees
  • CYCC N/A
  • TSBX N/A
  • Industry
  • CYCC Biotechnology: Pharmaceutical Preparations
  • TSBX
  • Sector
  • CYCC Health Care
  • TSBX
  • Exchange
  • CYCC Nasdaq
  • TSBX Nasdaq
  • Market Cap
  • CYCC 7.8M
  • TSBX 7.7M
  • IPO Year
  • CYCC N/A
  • TSBX 2023
  • Fundamental
  • Price
  • CYCC $16.04
  • TSBX $0.36
  • Analyst Decision
  • CYCC
  • TSBX Buy
  • Analyst Count
  • CYCC 0
  • TSBX 3
  • Target Price
  • CYCC N/A
  • TSBX $4.75
  • AVG Volume (30 Days)
  • CYCC 5.3M
  • TSBX 466.9K
  • Earning Date
  • CYCC 08-13-2025
  • TSBX 08-13-2025
  • Dividend Yield
  • CYCC N/A
  • TSBX N/A
  • EPS Growth
  • CYCC N/A
  • TSBX N/A
  • EPS
  • CYCC N/A
  • TSBX N/A
  • Revenue
  • CYCC $14,000.00
  • TSBX N/A
  • Revenue This Year
  • CYCC $137.21
  • TSBX N/A
  • Revenue Next Year
  • CYCC N/A
  • TSBX N/A
  • P/E Ratio
  • CYCC N/A
  • TSBX N/A
  • Revenue Growth
  • CYCC N/A
  • TSBX N/A
  • 52 Week Low
  • CYCC $3.08
  • TSBX $0.29
  • 52 Week High
  • CYCC $597.60
  • TSBX $2.59
  • Technical
  • Relative Strength Index (RSI)
  • CYCC 60.33
  • TSBX 50.70
  • Support Level
  • CYCC $10.05
  • TSBX $0.35
  • Resistance Level
  • CYCC $19.87
  • TSBX $0.37
  • Average True Range (ATR)
  • CYCC 3.57
  • TSBX 0.01
  • MACD
  • CYCC 1.99
  • TSBX -0.00
  • Stochastic Oscillator
  • CYCC 77.07
  • TSBX 43.75

About CYCC Cyclacel Pharmaceuticals Inc.

Cyclacel Pharmaceuticals Inc is a clinical-stage biopharmaceutical company that develops targeted medicines for cancer and other proliferative diseases. The company develops several families of anticancer drugs that act on the cell cycle, including CDK (cyclin-dependent kinase) inhibitors and PLK (polo-like kinase) inhibitors. The pipeline development programs of the company include fadraciclib and plogosertib. The company derives its revenue from United Kingdoms.

About TSBX Turnstone Biologics Corp.

Turnstone Biologics Corp is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The company is pioneering a differentiated approach to tumor-infiltrating lymphocytes, or TILs, a clinically validated technology for treating solid tumors. It is developing next-generation TIL therapies by selecting the most potent and tumor-reactive T cells, which are referred to as Selected TILs. TILs are a type of cell therapy that harnesses the patient's own immune cells to target their own tumors. TIL therapy involves the isolation of lymphocytes from the patient's tumor, expansion of the isolated cells outside the body, and then infusion of the cells back into the patient.

Share on Social Networks: